Weight Gain in Bipolar Disorder: Causes and Treatments

Primary Psychiatry

Volumn 10, Issue 11, 2003, Pages 29-33+36

  Printz, David ^a   Clark, Joy ^b   Stricks, Laurie ^a   Malaspina, Dolores ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; OLANZAPINE; PHENTERMINE; QUETIAPINE; RISPERIDONE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE; ZONISAMIDE;

ATAXIA; BIPOLAR DISORDER; BODY MASS; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; DISEASE ASSOCIATION; DIZZINESS; DRUG DEPENDENCE; EPIDEMIOLOGICAL DATA; EPILEPSY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INCIDENCE; INSULIN RESISTANCE; MANIA; MEMORY DISORDER; OBESITY; PARESTHESIA; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; SWEATING; WEIGHT GAIN; XEROSTOMIA;

EID: 1842507440     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation 2002;23:2696-2698.
2. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;1:76-79.
3. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;16:1523-1529.
4. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to obesity in the United States. Jama. 1999;16:1530-1538.
5. Elmslie JL, Silverstone JT, Mann JI, Williams SM, Romans SE. Prevalence of overweight and obesity in bipolar patients. J Clin Psychiatry. 2000;3:179-184.
6. Fagiolini A, Frank E, Houck PR, et al. Prevalence of obesity and weight change during treatment in patients with bipolar I disorder. J Clin Psychiatry. 2002;6:528-533.
7. McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry. 2002;3:207-213.
8. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990.
9. Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry. 1996;8:993-1000.
10. Chen Y, Silverstone T. Lithium and weight gain. Int Clin Psychopharmacol. 1990;3:217-225.
11. Vestergaard P, Poulstrup I, Schou M. Prospective studies on a lithium cohort. 3. Tremor, weight gain, diarrhea, psychological complaints. Acta Psychiatr Scand. 1988;4:434-441.
12. Henry C. Lithium side-effects and predictors of hypothyroidism in patients with bipolar disorder: sex differences. J Psychiatry Neurosci. 2002;2:104-107.
13. Chengappa KN, Chalasani L, Brar JS, Parepally H, Houck P, Levine J. Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review. Clin Ther. 2002;10:1576-1584.
14. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;4:392400.
15. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000;5:481-489.
16. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand. 1992;2:114-118.
17. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand. 1984;2:65-69.
18. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. Br Med J. 1981;6291:577-581.
19. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci. 1997;3:240-244.
20. Luef G, Abraham I, Haslinger M, et al. Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine, and valproic acid in 105 women. J Neurol. 2002;7:835-841.
21. Isojarvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol. 1996;5:579-584.
22. Isojarvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med. 1993;19:1383-1388.
23. Pylvanen V, Knip M, Pakarinen A, Kotila M, Turkka J, Isojarvi JI. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia. 2002;5:514-517.
24. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;6:1011-1017.
25. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002;12:1148-1155.
26. Devinsky O, Vuong A, Hammer A, Barrett PS. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology. 2000;4:973-975.
27. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001;2:172-177.
28. Biton V, Levisohn P, Hoyler S, Vuong A, Hammer AE. Lamotrigine versus valproate monothempy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J Child Neurol. 2003;2:133-139.
29. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry. 2000;11:841-850.
30. McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry. 2000;12:1025-1033.
31. Chengappa KN, Rathore D, Levine J, et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord. 1999;1:42-53.
32. Suppes T. Review of the use of topiramate for treatment of bipolar disorders. J Clin Psychopharmacol. 2002;6;599-609.
33. Skavoy T, Brodtkorb E. Weight loss in epileptic patients treated with topiramate. Acta Neurol Scand. 2003;6:428-429.
34. Ghaemi SN, Manwani SG, Katzow JJ, Ko JY, Goodwin FK. Topiramate treatment of bipolar spectrum disorders: a retrospective chart review. Ann Clin Psychiatry. 2001;4:185-189.
35. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder, a preliminary single-blind study. Bipolar Disord 2002;3:207-213.
36. Marcotte DB. Longer term treatment with topiramate for bipolar disorders. Bipolar Disord. 2001;3(suppl 1):46-47.
37. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;2:255-261.
38. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62(suppl 7):22-31.
39. Ganguli R. Weight gain associated with antipsychotic drugs. J Clin Psychiatry. 1999;60(suppl 21):20-24.
40. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs. 2001;7:537-551.
41. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;11:1686-1696.
42. Simpson MM, Goetz RR, Devlin MJ, Goetz SA, Walsh BT. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods. J Clin Psychiatry. 2001;9:694-700.
43. Bobes J, Rejas J, Garcia-Garcia M, et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: results of the EIRE study. Schizophr Res. 2003;1-2:77-88.
44. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999;5:702-709.
45. Sanger TM, Grundy SL, Gibson PJ, Namjoshi MA, Greaney MG, Tohen MF. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry. 2001;4:273-281.
46. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;2:92-100.
47. Jaton L, Kinon BJ, Rotelli M, Kollack-Walker S, Kaiser C. Differential rate of weight gain present among patients treated with olanzapine. Schizophr Res. 2003;60(suppl):357.
48. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;6:358-363.
49. Umbricht D, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry. 1994;9(suppl B):157-160.
50. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry. 2000;6:975-981.
51. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;1:16-22.
52. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry. 2003;182:141-147.
53. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology. 2003;28(suppl 1):83-96.
54. Keck P Jr., Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder a 4-week placebo-controlled trial. Psychopharmacology (Berl). 1998;2:173-184.
55. Keck PE Jr., Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;4:741-748.
56. Cohen S, Fitzgerald B, Okos A, Khan S, Khan A. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J Clin Psychiatry. 2003;1:60-62.
57. Jody D, Carson WH, Iwamoto T, et al. Meta-analysis of weight effects with aripiprazole. Schizophrenia Res. 2003;1:358.
58. Cordeiro O, Vallada H. Sibutramine-induced mania episode in a bipolar patient. Int J Neuropsychopharmacol. 2002;3:283-284.
59. Krempf M, Louvet JP, Allanic H, Miloradovich T, Joubert JM, Attali JR. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes Relat Metab Disord. 2003;5:591-597.
60. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized-controlled trial. JAMA. 2003;14:1820-1825.